Accueil   Diary - News   All news IXALTIS announces successful completion of phase 2 for its compound Litoxtine

IXALTIS announces successful completion of phase 2 for its compound Litoxtine

 

 

Toulouse (31) /Archamps (74), May, 14th, 2019 – Ixaltis is pleased to announce successful completion of the phase 2 of clinical development in urinary incontinence for its lead compound Litoxetine. Litoxetine is an SSRI (Selective Serotonin Reuptake Inhibitor) and serotonin agonist-antagonist with specific activities on some receptor subtypes. The positivie results pave the way to progress to phase 3 for this compound with the potential of being "first in class" for treating mixed urinary incontinence, a disease for which there is no appoved medical treatment on the market.

 

Read the press release